In a major metabolic research finding published in Nature on October 14, 2026, researchers supported by the National Institutes of Health (NIH) demonstrated that a widely prescribed blood-pressure drug activates energy-burning brown adipose tissue in humans. Unlike standard white fat that stores excess energy, brown fat actively consumes glucose and lipids to generate body heat, playing a crucial role in metabolic health, insulin sensitivity, and cardiovascular regulation. Utilizing an advanced artificial intelligence-driven clinical phenotyping platform, the research team analyzed extensive patient health records alongside molecular profiling to map medication interactions with thermogenic fat deposits. The data revealed that patients receiving specific antihypertensive regimens exhibited significantly higher brown fat activity, improved blood sugar control, and lower systemic inflammation compared to control groups. Endocrinologists and clinical pharmacologists praised the landmark discovery, observing that repurposing approved cardiovascular therapeutics to stimulate brown fat offers a novel, non-invasive therapeutic strategy for managing obesity, type 2 diabetes, and metabolic syndrome without requiring invasive interventions.

Uncovering New Metabolic Capabilities in Existing Cardiovascular Drugs

In a major breakthrough combining artificial intelligence with translational endocrinology, a study funded by the National Institutes of Health (NIH) revealed that the anti-hypertensive medication losartan stimulates thermogenic brown adipose tissue (BAT). Published in Nature by researchers at Rockefeller University, the study demonstrates that the angiotensin II receptor blocker (ARB)—traditionally used to manage hypertension and protect kidney function—also acts as an activator of health-promoting brown fat.

Unlike white fat, which stores excess energy and contributes to metabolic disease, brown fat functions as a caloric furnace, burning glucose and fatty acids to produce body heat through thermogenesis.

Overview: NIH-Funded Study Key Parameters and Findings

Study ParameterResearch Specifications & Clinical Data
Primary PublicationNature (October 14, 2026)
Lead Institution & SupportRockefeller University • Funded by the NIH
Investigated DrugLosartan (Angiotensin II Receptor Blocker)
Patient Cohort Analyzed100,000+ Electronic Health Records (AI clinical phenotyping)
Primary Biological ImpactBoosts Brown Adipose Tissue (BAT) volume & thermogenic metabolic rate
Observed Metabolic BenefitsLowered blood glucose, improved lipid profiles, & increased energy expenditure

AI-Enabled Phenotyping Connects Hypertensive Treatment to Brown Fat

To discover the link between cardiovascular medications and brown fat activity, the research team developed an AI-enabled clinical phenotyping framework. By training machine learning algorithms on thousands of PET-CT scans and electronic health records, researchers mapped anatomical locations of active brown fat—such as the supraclavicular and axillary regions—and cross-referenced them with prescription histories.

NIH Study Mechanism & Discovery Pipeline: ---------------------------------------- AI Analysis of 100,000+ PET-CT Records ──> Identification of High-BAT Cohorts ──> Losartan Correlation Isolated ──> Preclinical Metabolic Validation

The data revealed that patients taking losartan exhibited significantly higher levels of active brown fat compared to those on non-ARB anti-hypertensive regimens. Furthermore, patients with active brown fat demonstrated healthier glycemic parameters, lower systemic inflammatory markers, and reduced risk profiles for coronary artery disease and type 2 diabetes.

Preclinical Validation and Future Therapeutic Implications

Following the human epidemiological findings, researchers validated the mechanism in preclinical animal models. Healthy mice treated with losartan showed increased oxygen consumption, elevated carbon dioxide production, and enhanced metabolic rate without experiencing adverse weight loss or muscle wasting.

"There were plenty of other medications associated with brown fat activity in our large cohort," noted Dr. Paul Cohen, Associate Professor at Rockefeller University and senior author of the study. "This is just a start. The ultimate goal is finding ways to safely stimulate brown fat in individuals without high blood pressure, offering novel approaches to treat metabolic syndrome and type 2 diabetes."

The NIH-supported team plans to conduct prospective clinical trials to evaluate whether low-dose ARBs or selective receptor modulators can be repurposed to target obesity and metabolic disease safely in broader patient populations.